Literature DB >> 25027636

Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma.

Angelika Gutenberg1, Martin D Nischwitz2, Bastian Gunawan2, Christina Enders2, Klaus Jung3, Markus Bergmann4, Wolfgang Feiden5, Rupert Egensperger6, Kathy Keyvani6, Dietmar Stolke7, Ulrich Sure7, Henry W S Schroeder8, Rolf Warzok9, Ralf Schober10, Jürgen Meixensberger11, Werner Paulus12, Hansdetlef Wassmann13, Wolfgang Stummer13, Ingmar Blumcke14, Michael Buchfelder15, Frank K H van Landeghem16, Peter Vajkoczy17, Marlis Günther18, Jens Bedke19, Alf Giese20, Veit Rohde21, Wolfgang Brück22, Laszlo Füzesi2, Bjoern Sander23.   

Abstract

Synchronous (early) and metachronous (late) brain metastasis (BM) events of sporadic clear cell renal cell carcinoma (ccRCC) (n = 148) were retrospectively analyzed using comparative genomic hybridization (CGH). Using oncogenetic tree models and cluster analyses, chromosomal imbalances related to recurrence-free survival until BM (RFS-BM) were analyzed. Losses at 9p and 9q appeared to be hallmarks of metachronous BM events, whereas an absence of detectable chromosomal changes at 3p was often associated with synchronous BM events. Correspondingly, k-means clustering showed that cluster 1 cases generally exhibited low copy number chromosomal changes that did not involve 3p. Cluster 2 cases had a high occurrence of -9p/-9q (94-98%) deletions, whereas cluster 3 cases had a higher frequency of copy number changes, including loss at chromosome 14 (80%). The higher number of synchronous cases in cluster 1 was also associated with a significantly shorter RFS-BM compared with clusters 2 and 3 (P = 0.02). Conversely, a significantly longer RFS-BM was observed for cluster 2 versus clusters 1 and 3 (P = 0.02). Taken together, these data suggest that metachronous BM events of ccRCC are characterized by loss of chromosome 9, whereas synchronous BM events may form independently of detectable genetic changes at chromosomes 9 and 3p.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clear cell renal cell carcinoma; brain metastasis; chromosomal copy number alterations; comparative genomic hybridization (CGH); tumor progression

Mesh:

Substances:

Year:  2014        PMID: 25027636     DOI: 10.1016/j.cancergen.2014.05.004

Source DB:  PubMed          Journal:  Cancer Genet


  4 in total

Review 1.  Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy.

Authors:  Bassanelli Maria; Viterbo Antonella; Roberto Michela; Giacinti Silvana; Staddon Anita; Aschelter Anna Maria; D'Antonio Chiara; Marchetti Paolo
Journal:  Ther Adv Med Oncol       Date:  2016-07-25       Impact factor: 8.168

2.  Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.

Authors:  Jung Kwon Kim; Sung Han Kim; Mi Kyung Song; Jungnam Joo; Seong Il Seo; Cheol Kwak; Chang Wook Jeong; Cheryn Song; Eu Chang Hwang; Ill Young Seo; Hakmin Lee; Sung-Hoo Hong; Jae Young Park; Jinsoo Chung
Journal:  Cancer Med       Date:  2019-05-09       Impact factor: 4.452

3.  Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).

Authors:  Meichen Li; Xue Hou; Ke Sai; Lihong Wu; Jing Chen; Baishen Zhang; Na Wang; Lijia Wu; Hongbo Zheng; Jiao Zhang; Yonggao Mou; Likun Chen
Journal:  Oncoimmunology       Date:  2022-03-31       Impact factor: 8.110

4.  A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.

Authors:  Sung Han Kim; Yoon Seok Suh; Dong-Eun Lee; Boram Park; Jungnam Joo; Jae Young Joung; Ho Kyung Seo; Kang Hyun Lee; Jinsoo Chung
Journal:  Oncotarget       Date:  2017-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.